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Summary PurposeThe IGF-1R signaling pathway has been
implicated in multiple cancers as important for cell survival,
proliferation, invasion and metastasis. BIIB022 is a non-
glycosylated human IgG4 monoclonal antibody (mAb) with
specificity for IGF-1R. Unlike other anti-IGF1R antibodies,
BIIB022 has no effector functions. Additionally, inhibition is
via an allosteric rather than competitive mechanism, which
further differentiates this antibody from others. We sought to
determine the safety and tolerability of BIIB022 and deter-
mine the pharmacokinetic (PK) and pharmacodynamic (PD)
profile of this antibody.MethodsA multi-institutional phase I
study evaluated the safety of escalating doses of BIIB022
given IV q3wk until progression or unacceptable toxicity in
patients with advanced solid tumors. Five sequential BIIB022
dose cohorts were evaluated using a standard 3+3 dose-
escalation design (1.5, 5. 10, 20, 30 mg/kg); 10 additional
patients were treated at the recommended phase 2 dose.
Results 34 patients were treated. Toxicities were manageable
and mostly low grade; grade 3–4 hyperglycemia was not
observed. No RECIST responses were observed, although
three patients had metabolic responses associated with
prolonged stable disease. The PK of BIIB022 was nearly
linear in the dose range from 10 to 30 mg/kg, with some
nonlinearity at lower doses (1.5–5.0 mg/kg), likely due to
target-mediated drug disposition of BIIB022 at low serum
concentrations. PD analyses showed decrease in IGF-1R
levels on leucocytes, with stable serum values of IGF-1 and
IGF-2. ConclusionsBIIB022 can be safely given at 30 mg/kg
IV every 3 weeks with preliminary evidence of biological
activity in selected patients.
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Introduction
The IGF-1R signaling pathways is critical for cancer survival
and proliferation as evidenced by decreased tumor cell
growth, survival, motility and invasion when it is blocked
[1–3]. Individuals with higher than normal circulating levels
of IGF-1 have an elevated risk of developing breast, prostate,
lung, and colon cancers [3]. In addition, elevated levels of the
IGF-1R ligands, IGF-1 and IGF-2, have been found in patients
with breast cancer [4, 5], and in the tumor microenvironment
in colorectal tumors [6, 7]. Perturbation with an anti-IGF-1R
antibody of IGF-1R axis is therefore hypothesized to have
therapeutic value.
BIIB022 is a non-glycosylated human IgG4 monoclonal
antibody with specificity for IGF-1R. It inhibits the binding of
both IGF-1 and IGF-2 to the receptor via an allosteric mech-
anism, interacting with an epitope on the fibronectin III-1
domain of IGF-1R that is distinct from the IGF-1 and IGF-2
binding region [8]. BIIB022 blocks both IGF-1 and IGF-2
induced phosphorylation of IGF-1R and downstream sub-
strates, thereby inhibiting ligand-mediated receptor signaling.
Additionally, BIIB022 was designed without Fc effector func-
tion and C1q binding and therefore cannot activate antibody-
dependent cell-mediated cytotoxicity (ADCC) or
complement-dependent cytotoxicity (CDC), features that
may limit toxicity associated with this agent. In vitro studies
demonstrated evidence of decreased cell growth following
treatment with BIIB022 in lung, pancreas and colon cancer
cell lines in the presence of IGF-1 or IGF-2 in culture media
[9].
We performed a multi-institutional phase I study of
BIIB022 to determine the maximally tolerated dose (MTD),
toxicity profile and pharmacokinetic properties of this anti-
body in patients with advanced malignancies.
Materials and methods
Subject selection
Patients with relapsed or refractory solid tumors age 18 or
above were screened for eligibility after providing written
informed consent. Patients were required to have at least
evaluable disease, life expectancy of 3 months or more and
an ECOG score of 0–1. Prior therapy was allowed except for
prior anti-IGF-1R therapy or prior anti-cancer therapy within
4 weeks of initiation of BIIB022. Other eligibility criteria
included adequate hematologic, renal, and hepatic function;
no history of diabetes mellitus; and hemoglobin A1c≤6.
Study design
This was a multi-institutional phase I study to determine the
safety, tolerability, and MTD of BIIB022 by intravenous (IV)
infusion every 3 weeks. BIIB022 was produced in Chinese
Hamster Ovary cells and formulated as a sterile liquid at a
concentration of 10 mg/ml. Subjects were enrolled into five
sequential BIIB022 dose cohorts (1.5, 5, 10, 20, 30 mg/kg),
with no intra-subject dose escalation. Each subject was eval-
uated for dose-limiting toxicities (DLTs) during the first
28 days. Enrollment into the next higher dose cohort was
not permitted unless 0 of 3 or ≤1 of 6 subjects in the previous
cohort had DLTs. Subjects who did not receive at least two
initial doses of BIIB022 and did not experience a DLT were
replaced. DLT was defined as any clinically significant grade
≥3 toxicity regardless of relatedness to BIIB022, including
nausea/vomiting and diarrhea if grade ≥3 despite adequate
supportive care measures, or treatment delays of ≥14 days
due to toxicity. Toxicities were graded according to NCI
CTCAE version 3. The study was amended once to collect
additional safety assessments: insulin concentration and C-
peptide to evaluate hyperglycemia, creatinine kinase to eval-
uate for muscle damage, prostate-specific antigen (PSA) to
evaluate effects on the prostate as well as additional immuno-
genicity analyses. Extra electro-cardiograms were added in
response to a DLT of QTc prolongation in this study and
routine audiometry assessments were added in response to
an ototoxicity DLT seen in contemporaneous phase I clinical
trials of other anti-IGF-1R antibodies. Therapy with BIIB022
was continued until disease progression, unacceptable toxici-
ty, or subject withdrawal.
The recommended Phase 2 dose (RP2D) was determined
by evaluating safety and pharmacokinetic (PK) data after all
the cohorts completed enrollment and all subjects had been
followed for at least 28 days after their first BIIB022 infusion.
The RP2D was defined as the MTD, biologically–effective
dose (BED), or 30 mg/kg if the MTD or BED were not
reached. The BED was defined as the dose at which BIIB022
serum exposure had reached a plateau in 2 successive dose
cohorts (indicating receptor saturating exposure), or the
BIIB022 dose resulting in human exposure approximately
10 times higher than serum levels associated with maximal
anti-tumor activity in animal xenograft models. An additional
10 subjects were treated at RP2D to further evaluate safety,
with emphasis on evaluating any evidence of cumulative
toxicity. Secondary endpoints included PK and immunoge-
nicity assessments, as well as efficacy using RECIST. Serum
samples for BIIB022 concentration determination and anti-
BIIB022 antibody formation were collected after the last
dose and once a month for 2 months, as long as clinically
indicated. Exploratory objectives included biomarker eval-
uation of archival tumor tissue and peripheral blood as well
as FDG-PET scans.
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The study was approved by the institutional review board
or independent ethics committee at each of the participating
centers, and was performed in accordance with federal and
institutional guidelines, observing the standards set by the
Helsinki Declaration.
Anti-tumor activity
Response was determined by imaging studies performed ev-
ery 2 cycles using RECIST version 1.0. Metabolic response
was assessed by FDG-PET at baseline and again between
weeks 1 and 3 of treatment utilizing the criteria developed
by the European Organization for Research and Treatment of
Cancer (EORTC) [10].
Pharmacokinetics
Blood samples for determining PK were drawn cycle 1 at
baseline; 15 and 45 min, 1.5, 3, 5, 8, 24, and 96 h and on
days 8 and 15 following completion of the BIIB022 infusion.
Sparse sampling for PK was performed at 15 min and days 8
and 15 following all subsequent BIIB022 doses. BIIB022
serum concentrations were determined by an enzyme-linked
immunosorbent assay (ELISA), performed at Biogen Idec,
(La Jolla, CA). In brief, plates were coated with mouse anti-
human IGF-1R followed by a secondary coating of recombi-
nant human IGF-1R. BIIB022 levels were detected with
mouse anti-human IgG4-HRP. LLOQ of the assay was
160 ng/ml. Noncompartmental PK analysis was conducted
on the concentration-time data for each subject using
WinNonlin (Pharsight Co. version 5.2). Statistics were then
calculated for the resulting PK parameters in each dose cohort.
Pharmacodynamics
IGF1R down-regulation was measured on blood granulocytes
on Day 1 (pre- and post-infusion), Day 2, and Day 5 of Cycles
1 and 2. Flow cytometric analyses to determine the expression
of IGF-1R on the surface of granulocytes were performed at
Biogen Idec (La Jolla, CA). The chimeric IgG4.P.agly anti-
IGF1R MAb P1E2 was used to assess receptor downregula-
tion: the MAb probe binds to IGF1R on blood granulocytes,
and does not compete with BIIB022 allowing qantitation of
IGF1R levels in the presence of BIIB022. IGF1 and IGFBP3
levels were measured in the serum using validated in vitro
diagnostic approved immunoassay kits from Diagnostic Sys-
tems Laboratories Corp. (Webster, TX).
Statistics
The study was a multi-institutional phase I trial that utilized a
standard 3+3 dose-escalation design based on the observed
toxicities in cycle 1. The study population for safety analyses
included all patients who received at least one dose of
BIIB022. The DLT-evaluable population included all patients
who met DLTassessment criteria as described above. The PK-
evaluable population included all patients for whom PK sam-
pling was completed on at least 1 day. The efficacy-evaluable
population included all patients with measurable disease at
baseline. Descriptive statistics were used to summarize patient
characteristics, treatment administration/compliance, safety,
PK parameters, and efficacy.
Results
Thirty-five patients were enrolled at 3 centers in the United
States. Thirty-four patients received at least one infusion of
BIIB022. Table 1 summarizes the demographics of the treated
patients; this was a population with advanced malignancies,
76% of whom had 2 or more sites of metastases, and 100% of
whom had received prior chemotherapy.
Toxicity
All treated subjects experienced at least 1 adverse event,
primarily grade 1 or 2 (see Tables 2 and 3), with 91 % of
them reported as related to BIIB022. Related AEs reported in
10 % or more of patients included: headache, fatigue, dizzi-
ness, nausea, and muscle spasms. There were no patients with
grade 3 or 4 hyperglycemia; in addition there was no evidence
for increasing serum insulin or fructosamine levels over time
or at increased BIIB022 doses. Twenty-one percent of subjects
experienced a Grade 3 treatment-related AE. This included 1
subject in the 1.5 mg/kg dose cohort (deep vein thrombosis); 2
subjects in the 10 mg/kg dose cohort (hypertension and dys-
pnea); 2 subjects in the 20 mg/kg dose cohort (asthenia and
ECG QTc prolonged); and 2 subjects in the 30 mg/kg dose
cohort (pulmonary congestion and fatigue in 1 subject and
gastrointestinal (GI) hemorrhage in 1 subject). There were no
grade 5 DLTs. The four deaths reported on study were due to
disease progression.
There were two patients who experienced DLT. A
57 year old woman with colorectal cancer and no prior
history of heart disease treated at 20 mg/kg was found to
have an asymptomatic grade 2 T-wave inversion and grade
3 prolonged QTc on ECG on day 26. There was no evi-
dence of ischemia or infarction and an echocardiogram
revealed transient decreased apical wall motion. This was
judged possibly related to BIIB022, and the patient was
removed from study and recovered without sequelae. A
total of six patients were treated with BIIB022 20 mg/kg
without further DLTs, including ECG changes. In addition,
subsequent patients were monitored for QTc prolongation
with the median maximum change found to be 25.7 msec
from baseline.
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The second DLT occurred at the 30 mg/kg dose level in a
26 year old patient with small round blue cell sarcoma. Prior to
study entry the patient had experienced bleeding from tumor
in the jejunum. On day 22 following his first infusion, the
patient developed a grade 3 GI bleed, which was felt to be
unlikely related to BIIB022. Although the GI bleed was most
likely related to the tumor, a contribution from BIIB022 could
not be ruled out, and it was considered a DLT based on the
definitions set forth in the protocol. The patient was with-
drawn from the study and no further DLTs were noted at this
dose level. An additional patient at the 30 mg/kg level was
removed from study after being diagnosed with
myelodysplastic syndrome. This was not considered second-
ary to BIIB022 as the patient had received extensive prior
therapy with cytotoxic chemotherapies, including very
prolonged treatment with doxorubicin.
Pharmacokinetics
Mean BIIB022 serum concentration versus time data for all
dose cohorts are plotted in Fig. 1. Serum exposure increased in
a dose-dependent manner, but BIIB022 demonstrated nonlinear
PK, as indicated by the plot of AUCinf versus Dose in Fig. 2.
The steady-state volume of distribution approximated blood
volume at all dose levels, which is consistent with distribution
volumes reported for other monoclonal antibodies.
Table 2 Incidence of most com-
mon (≥10 %) and all severe AEs
related to BIIB022
Toxicity grade Total
1 2 3 4 5
Headache 18 (53 %) 2 (6 %) 0 0 0 20 (59 %)
Fatigue 4 (12 %) 5 (15 %) 1 (3 %) 0 0 10 (29 %)
Dizziness 2 (6 %) 3 (9 %) 0 0 0 5 (15 %)
Nausea 4 (12 %) 1 (3 %) 0 0 0 5 (15 %)
Muscle spasms 2 (6 %) 3 (9 %) 0 0 0 5 (15 %)
Hypertension 0 1 (3 %) 1 (3 %) 0 0 2 (6 %)
Dyspnea 0 1 (3 %) 1 (3 %) 0 0 2 (6 %)
asthenia 1 (3 %) 0 1 (3 %) 0 0 2 (6 %)
Gastrointestinal hemorrhage 0 0 1 (3 %) 0 0 1 (3 %)
Deep vein thrombosis 0 0 1 (3 %) 0 0 1 (3 %)
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Prior chemotherapy 34 (100)
Range: 1–27
Median: 7.5
Table 3 All grade 3 AEs related to BIIB022








QT prolongation Possibly 20
Gastrointestinal haemorrhage Unlikely 30
Fatigue Possibly 30
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Pharmacodynamic studies
IGF-1R levels declined shortly after BIIB022 dosing in all dose
cohorts. There was no apparent dose–response relationship
found. IGF-1R levels remained low throughout treatment while
granulocyte counts remained relatively constant. In addition,
median IGF-1 serum levels showed no change through day 15
of cycle 3 except for in the 10 mg/kg dose cohort, which likely
reflected the effect of one outlier. Mean levels of IGF-BP3
serum levels were also unchanged through day 15 of cycle 3.
Anti-tumor activity
Patients were evaluated for efficacy by investigators every 5–
6 weeks using RECIST (version 1.0). Efficacy data are
available on 24 pts (3 in 1.5 mg/kg cohort, 2 in 5 mg/kg
cohort, 3 in 10 mg/kg cohort, 5 in 20 mg/kg cohort, and 11
in 30 mg/kg cohort). There were no complete or partial
responses. Fifty nine percent of patients (n=20) had stable
disease as best response, while 29 % (n=10) had progressive
disease and 12 % (n=4) were not evaluable for response. Six
patients with sarcoma remained progression free for 3.75
(30 mg/kg), 4.5 (2 patients at 30 mg/kg), 5.25 (5 mg/kg),
and 6 months 1.5 mg/kg and 20 mg/kg; of these, 3 patients
had retroperitoneal liposarcoma.
Metabolic response was also assessed by FDG-PET scan at
baseline and during treatment (1 week after 1st infusion and
before 3rd infusion). Thirty-two patients had PET imaging at
baseline and during cycle 1 (day 8) and prior to cycle 3.
Twenty-eight percent (9 of 32) had a decline in SUV of
>25 % (see Table 4). The median number of cycles on study
in patients with PET responses was 7 versus those patients
with stable or progressive disease in which the median number
of cycles was 2.5.
Notably, 7 of these 9 patients with SUV declines of >25 %
were diagnosed with sarcoma. Metabolic responses correlated
with disease stabilization for more than 4 months in 4 of these
patients. The first was a 58-year old male with Stage IV
liposarcoma enrolled in 1.5 mg/kg cohort. FDG uptake on
cycle 1, day 8 had decreased by 34 % from baseline. He
received 10 infusions of BIIB022 andmaintained stable disease
for 7months. A second patient was a 66 year old male also with
metastatic retroperitoneal liposarcoma. FDG uptake on cycle 1,
day 8 demonstrated a mixed response with one stable lesion
and another with a 38 % increase in SUV. A repeat study cycle
2 day 20 demonstrated a 31 % decrease in the initially stable
lesion and a return to baseline of the lesion of the second lesion.
He received 7 months of 20 mg/kg BIIB022 before progressing
by RECIST. The third patient was a 59-year old male with
spindle cell carcinoma who was enrolled in the 30 mg/kg
cohort. His FDG uptake on day 43, after 2 BIIB022 doses,
had decreased by 40 % compared with baseline. He received 7
infusions of BIIB022 and had stable disease for 4 months.
Lastly, a patient with adrenal carcinoma at the 30 mg/kg cohort
remained on study for 10 cycles. His FDG uptake on cycle
1 day 8 had decreased by 30 % compared to baseline.
Discussion
In this phase I trial of BIIB022 monotherapy, we found that
therapy was generally well-tolerated at doses up to 30 mg/kg
given every 3 weeks in patients with relapsed and refractory
solid tumors. A low incidence of grade 3 toxicities was
observed, and no grade 4 or 5 toxicities. There was prelimi-
nary evidence of biologic activity; more than in 25 % of
patients had metabolic responses and 8 patients were without
progressive disease for 3.75 months (5 cycles) or longer.
Fig. 1 Mean BIIB022 concentration versus time
Fig. 2 Mean AUC versus dose of BIIB022
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BIIB022 has a unique structure compared with other anti-
bodies targeting IGF-1R. Ganitumab (AMG-479), R1507,
and daltuzumab (MK-0646) are humanized IgG1 antibodies
while figitumimab (CP-751,871) is a humanized IgG2 anti-
body [11–13]. By contrast, BIIB022 is a non-glycosylated
human IgG4 monoclonal antibody that lacks Fc effector and
C1q binding domains. Potential benefits of this unique struc-
ture are improved toxicity because of lack of CDC, which was
supported by the absence of any observed infusion reac-
tions in our trial. All the IGF-1R targeting antibodies have
been shown to bind to IGF-1R. Daltuzumab is the only
agent reported to be able to bind to IGF-1R hybrid recep-
tors. Once these antibodies bind IGF-1R or hybrid recep-
tors, they prevent binding of the ligands IGF-1 and IGF-2
(R1507 does not block IGF-2) thereby blocking ligand
induced phosphorylation of the receptor. Unlike the other
antibodies in development, BIIB022 interferes with recep-
tor function via an allosteric mechanism, as it binds an
epitope on the fibronectin III-1 domain of IGF-1R that is
distinct from the IGF-1 and IGF-2 binding regions [8].
Thus, BIIB022 can engage IGF-1R in the presence of
ligands and is hypothesized to cause a conformational
change that significantly reduces ligand affinity for the
receptor.
Toxicities observed in our study were consistent with those
previously reported with this class of therapeutic agents.
While toxicities (all grades) were reported in all patients, the
proportion of patients with grade 3 toxicities related to
BIIB022 was only 21 %. Unlike reports from other phase I
studies of IGF-1R targeting antibodies, we did not observe
any hyperglycemia, although we excluded patients with a
history of diabetes mellitus or patients with baseline hemo-
globin A1c of >6 %, a lower cut-off than other studies that
used 8 % as the eligibility criterion. We did note some cardio-
vascular effects that may have been attributable to BIIB022,
including one patient with hypertension and a second with
asymptomatic EKG changes including T-wave inversion and
QTc prolongation. IGF-1 has been shown in preclinical
models to aid in survival of myocardium in the setting of
ischemia. Consequently, our clinical findings cannot exclude
a causal relationship to BIIB022 therapy. A deep venous
thrombosis was noted in one of our patients, which is not
uncommon in patients with advanced malignancies. We note
that cerebral ischemia was reported in a patient treated with
R1507. It seems unlikely that either of these events were drug
related as there are no data to date showing that inhibition of
IGF-1R perturbs coagulation and patients with metastatic
cancers are known to be hypercoagulable.
Table 4 PET response data
Dose level mg/kg Diagnosis Baseline max
SUV
Cycle 1 Max SUV
(% change from baseline)
Cycle 3 Max SUV
(% change from baseline)
Number of cycles
on study
1.5 Retroperitoneal sarcoma 15.90 10.50 (−33.96) 9.9 (−37.74) 8
5.0 Synovial sarcoma 1.85 1.25 (−34.83) 1.40 (−26.67) 7
20.0 Rhabdomyosarcoma 6.15 4.80 (−22.12) 4.25 (−31.71) 4
20.0 Adrenal cortical Ca 12.7 9 (−29.13) 12.3 (−0.03) 10
30.0 Spindle cell sarcoma 7.50 4.70 (−38.74) 4.25 (−44.71) 5
30.0 Ewing’s sarcoma 6.55 3.30 (−50.47) 4.13 (−37.96) 3
30.0 Adenosarcoma of uterus 5.30 3.05 (−42.69) 4.70 (−11.13) 4
30.0 High grade spindle cell sarcoma NOS 3.55 ND 2.15 (−39.74) 7
Table 5 Pharmacokinetic parameters
Pharmacokinetic parametera BIIB022 dose (mg/kg)
1.5 (N=4) 5 (N=3) 10 (N=3) 20 (N=6) 30 (N=18)
Cmax (μg/mL) 29.8±6.13 82.6±7.13 172±70.7 412±78.2 801±48.0
AUCinf (day
aμg/mL) 164±45.3 559±166 2160±1260 5610±2260 9330±2310
CL (L/day) 0.686±0.107 0.734±0.267 0.327±0.078 0.268±0.108 0.262±0.085
t1/2 (day) 4.72±0.401 5.12±2.01 13.7±5.24 15.2±6.64 15.4±5.71
Vss (L) 4.18±0.519 5.37±1.03 6.00±1.36 4.94±0.221 5.34±2.23
a Data presented are the mean ± standard deviation from dose 1 only
Cmax maximum-observed serum concentration, AUC area-under-the concentration time curve, CL clearance, t1/2 terminal half-life, Vss volume of
distribution at steady-state
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The pharmacokinetic data demonstrated a dose dependen-
cy, but were not linear. The nonlinearity in PK at the lower
doses is likely due to target-mediated disposition of
BIIB022 at serum concentrations below 20 μg/mL denoted
by the horizontal line on Fig. 1. At higher concentrations, we
hypothesize that target-mediated pathway becomes saturated,
and the non-specific FcRN-mediated clearance pathway pre-
dominates. Consistent with this hypothesis, the data in Table 5
shows that the apparent clearance of BIIB022 was 0.69–
0.73 L/day at the lower dose levels but settled into a range
from 0.26 to 0.33 L/day at doses of 10 to 30 mg/kg. Likewise,
the mean observed terminal t1/2 increased from 4.7 to 5.1 days
at the lower doses to 13.7–15.4 days at 10 to 30 mg/kg,
consistent with a shift from target-mediated clearance at the
lower dose levels to nonspecific clearance at the higher dose
levels. In the linear PK range the clearance of BIIB022 was
0.27–0.33 L/day, the steady-state distribution volume was
4.9–6.0 L, and the terminal elimination half-life was 14–
15 days. The PK characteristics of BIIB022 are typical of
those reported for other monoclonal antibodies. The terminal
half-life supports a 3-week dosing schedule for chronic ad-
ministration of BIIB022.
We did not observe any RECIST responses, although 9/32
(28%) patients treatedwith BIIB022 had ametabolic response as
defined by the EORTC criteria. Interestingly, 4 of these patients
also had prolonged stable disease, 3 of whom were treated at
20 mg/kg. Although a quantitative link between BIIB022 expo-
sure required for efficacy in animals and humans has not been
established, at a dose of 20 mg/kg IV q 3 weeks, BIIB022
achieved trough serum levels in human subjects comparable to
levels that consistently demonstrated anti-tumor activity in sev-
eral mouse xenograft tumor models. Other IGF-1R inhibitor
studies have demonstrated mixed or partial responses in patients
with Ewing’s Sarcoma and neuroendocrine tumors [11–15]. In
our patient population we did not have any patients with neuro-
endocrine tumors. Our largest group of patients on study had a
diagnosis of sarcoma (Table 1). We only treated 1 patient with
Ewing’s Sarcoma/PNET, who received 4 cycles prior to disease
progression. A second patient with a small round blue cell tumor
experienced the tumor-related gastrointestinal bleed and DLT. Of
note we did see prolonged stable disease in 3 of 6 liposarcoma
patients which is interesting as IGF-1R has been reported as a
potential therapeutic target in liposarcomas [16].
Biomarker studies demonstrated down regulation of IGF-
1R levels on blood granulocytes, with no significant changes
in the levels of IGF-1R’s stimulatory and inhibitory ligands
IGF-1 and IGFBP-3. This is in contrast to other antibodies
where an increase in IGF-1 has been documented [11–13]. For
example, at the 9 mg/kg dose of R1507, IGF-1 increased by
250 % from baseline and after 7 doses the mean percentage
ranged from 100 to 350 % for all dose levels[12]. The only
study reporting levels of the inhibitory ligand IGF-BP3 also
noted an increase in these levels[13]. The difference in the
levels of stimulatory or inhibitory ligands is of unclear signif-
icance. Studies of other targeted therapies have reported in-
creases in the concentration of receptor ligands over time [17,
18]. A key difference may be that BIIB022, unlike all the other
IGF-1R antibodies, is not a competitive inhibitor of the ligand
binding sites, which might explain the lack of alteration of
these levels. An alternative explanation of the lack of effect on
ligands is that BIIB022 for some reason was not having a
therapeutic effect. Against this interpretation, however, is the
observed decrease in IGF-1R levels on PMNs as well as the
metabolic responses on PET scans. We only collected serum
levels of ligands and therefore cannot comment on effects on
intratumoral ligand levels, which would require on-study
biopsies.
In conclusion, BIIB022 was found to be well tolerated
at doses ranging from 1.5 to 30 mg/kg given intravenous-
ly every 3 weeks. The toxicity profile was similar to other
anti-IGF-1R mAbs with the exception of hyperglycemia,
which was not observed in our study, and our observation
of prolonged QTc associated with a transient wall motion
abnormality in one patient receiving BIIB022. In general,
the therapeutic benefits of IGF-1R inhibitors have been
disappointing, but there have been some limited responses
and instances of disease stabilization in patients with
sarcomas [12, 14, 15, 19]. This suggests that IGF-1R
inhibitors may yet play a role in the anti-cancer armamen-
tarium, if a reliable biomarker of disease sensitivity can be
found in order to allow for rational patient selection and
optimization of the risk:benefit ratio.
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